Rosetta Genomics Appoints Dr. Maria Fe Paz as Interim Chief Medical Officer

Accomplished Medical Executive in Molecular Diagnostics and Precision Medicine Brings Global Experience in Cutting Edge Oncology Diagnostics

PHILADELPHIA & REHOVOT, Israel--()--Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the appointment of Maria Fe Paz, M.D. Ph.D., effective immediately, as a medical affairs consultant in the role of Interim Chief Medical Officer, with plans to transition her to Chief Medical Officer of Rosetta Genomics upon receipt of a valid work visa that supports her planned relocation to the U.S.

Dr. Paz is an accomplished chief medical officer with nearly 15 years’ of experience in the pharmaceutical and biomedical industry, with demonstrated achievements in molecular diagnostics, translational and precision medicine.

“We are delighted to welcome Dr. Paz to the Rosetta Genomics team to lead medical affairs, which is a key area for the Company as we expand our footprint in precision medicine. Maria’s significant clinical and corporate experience and her depth of knowledge in molecular diagnostics, epigenomics, oncology and biomarkers make her ideally suited to lead our medical efforts. Importantly, her relationships with key thought leaders in oncology and global pharmaceutical and biotechnology companies will be a valuable asset for the Company as we expand our research and development efforts including our pursuit of predictive biomarkers in immune-oncology,” commented Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.

“I am confident Maria will be an outstanding member of our executive leadership team as she shares our passion for advancing personalized medicine in order to enhance quality of life for patients,” added Mr. Berlin.

Dr. Paz joins Rosetta Genomics from Labceutics and the Diaceutics Group, where she was the Founder-President and Chief Medical Officer, respectively. In this role, she combined her extensive knowledge of the global laboratory landscape and personalized medicine to establish a global laboratory network for the successful implementation of companion diagnostics for major pharmaceutical and diagnostic companies. Prior to joining Diaceutics and founding Labceutics, Dr. Paz was head of translational medicine and scientific development at Zeltia SA., a biopharmaceutical company, where she forged important relationships with international labs and hospitals, and gained over 10 years’ experience establishing and managing laboratories for molecular diagnostics and precision medicine. In Dr. Paz’s earlier experience, she founded and served as the Scientific-Medical Consultant for Epicure Molecular, where she was responsible for advising on the pharmacogenetics and molecular diagnostic strategies for drug and biomarker development to pharmaceutical companies. Dr. Paz was the Head of the Epigenetics Unit at the Spanish National Cardiovascular Centre (CNIC), and was the founder and director of Molecular and Genetic Diagnostics Laboratories in Hospital de Madrid. She began her career as a principal scientist at the Spanish Biotechnology Centre (CSIC). Dr. Paz received her B.A. in Molecular Biology and M.D. at the Universidad Autónoma de Madrid, and holds a Ph.D. from the Spanish National Cancer Center. Dr. Paz was a Predoctoral Fellow at the Sydney Kimmel Cancer Center at Johns Hopkins University and a Postdoctoral Fellow at the Spanish National Cancer Centre.

Dr. Paz is recognized as an award-winning researcher, authoring more than two dozen publications in peer-reviewed journals. She serves as an active member of the American Society of Clinical Oncology, the European Society of Medical Oncology, and the American Association of Cancer Research and the Spanish Association of Cancer Research.

Commenting on her appointment, Dr. Paz said, “I am excited to be joining Rosetta Genomics at this juncture in its growth trajectory. Rosetta’s recent acquisition of PersonalizeDx expanded its broad suite of oncology diagnostics that provides physicians with critical and objective actionable data to select optimal treatment options and improve patient outcomes. I look forward to working with the Rosetta team to help increase awareness of, and demand for, its clinically important portfolio of high-value molecular testing services, create new relationships with third parties such as pharmaceutical, biotech and molecular diagnostic companies as well as in helping set the course for future research and development activities leveraging Rosetta’s leading, microRNA biomarker platforms, all with the aim of bringing truly personalized medicine to patients.”

Dr. Paz will be providing her services as a consultant through a third party corporation, until she is granted a valid U.S. work visa.

About Rosetta Cancer Testing Services

Rosetta Cancer Tests are a series of microRNA-based and other genomic diagnostic testing services offered by Rosetta Genomics. The Rosetta Cancer Origin Test can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). The Rosetta Lung Cancer Test accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. The Rosetta Kidney Cancer Test accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma. RosettaGX Reveal accurately classifies indeterminate thyroid nodules. In the U.S. alone, Rosetta Genomics estimates that 150,000 patients a year may benefit from the Rosetta Cancer Origin Test, 62,000 patients a year may benefit from the Rosetta Kidney Cancer Test™, 222,000 patients a year may benefit from the Rosetta Lung Cancer Testand 150,000 a year may benefit patients from RosettaGX Reveal. The Company’s assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. In addition to its proprietary products, the Company markets the Rosetta Genomics OncoGxOne, OncoGxLung, PGxOneand EGFR and KRAS tests for Admera Health. With the acquisition of PersonalizeDx, the Company now offers a broader menu of molecular and other assays for bladder, lung, prostate and breast cancer patients. For more information, please visit www.rosettagenomics.com. Parties interested in ordering any of these tests can contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta Genomics

Rosetta develops and commercializes a full range of microRNA-based and other molecular diagnostics. Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Through the acquisition of PersonalizeDx, the Company offers core FISH, IHC and PCR-based testing capabilities and partnerships in oncology and urology that provide additional content and platforms that complement the Rosetta offerings. Rosetta’s and PersonalizeDx’s cancer testing services are commercially available through the Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs, respectively. For more information visit www.rosettagenomics.com.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including but not limited to statements relating to Rosetta’s expanding its footprint in precision medicine, Rosetta expanding its research and development efforts including our pursuit of predictive biomarkers in immune-oncology, and Dr. Paz ‘s potential contribution to Rosetta, the potential increase in awareness and demand for Rosetta’s test portfolio, Rosetta creating new relationships with third parties, Rosetta’s future research and development activities bringing personalized medicine to patients and Dr. Paz actually receiving a valid U.S. work visa in the allotted timeframe constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2014 as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Contacts

Rosetta Genomics
Ken Berlin, 609-419-9003
President & CEO
investors@rosettagenomics.com
or
Investors:
LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com

Contacts

Rosetta Genomics
Ken Berlin, 609-419-9003
President & CEO
investors@rosettagenomics.com
or
Investors:
LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com